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Abstract
Background-The purpose of this study was to assess the effect of 8-weeks ingestion of a commercialized joint pain dietary 
supplement (InstaflexTM Joint Support, Direct Digital, Charlotte, NC) compared to placebo on joint pain, stiffness, and 
function in adults with self-reported joint pain. InstaflexTM is a joint pain supplement containing glucosamine sulfate, 
methylsufonlylmethane (MSM), white willow bark extract (15% salicin), ginger root concentrate, boswella serrata extract 
(65% boswellic acid), turmeric root extract, cayenne, and hyaluronic acid.
Methods- Subjects included 100 men and women, ages 50-75 years, with a history (>3 months) of joint pain, and were 
randomized to Instaflex™ or placebo (3 colored gel capsules per day for 8 weeks, double-blind administration). Subjects 
agreed to avoid the use of non-steroidal anti-inflammatory drugs (NSAID) and all other medications and supplements 
targeted for joint pain. Primary outcome measures were obtained pre- and post-study and included joint pain severity, 
stiffness, and function (Western Ontario and McMaster Universities [WOMAC]), and secondary outcome measures 
included health-related quality of life (Short Form 36 or SF-36), systemic inflammation (serum C-reactive protein and 9 
plasma cytokines), and physical function (6-minute walk test). Joint pain symptom severity was assessed bi-weekly using a 
12-point Likert visual scale (12-VS).
Results-  Joint pain severity was significantly reduced in Instaflex™ compared to placebo (8-week WOMAC, ↓37% versus 
↓16%, respectively, interaction effect P=0.025), with group differences using the 12-VS emerging by week 4 of the study 
(interaction effect, P=0.0125). Improvements in ability to perform daily activities and stiffness scores in Instaflex™ compared 
to placebo were most evident for the 74% of subjects reporting knee pain (8-week WOMAC function score, ↓39% versus 
↓14%, respectively, interaction effect P=0.027; stiffness score, ↓30% versus ↓12%, respectively, interaction effect P=
0.081). Patterns of change in SF-36, systemic inflammation biomarkers, and the 6-minute walk test did not differ 
significantly between groups during the 8-week study
Conclusions-Results from this randomized, double blind, placebo-controlled community trial support the use of the 
Instaflex™ dietary supplement in alleviating joint pain severity in middle-aged and older adults, with mitigation of difficulty 
performing daily activities most apparent in subjects with knee pain.
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Background: The purpose of this study was to assess the effect of 8-weeks ingestion of a commercialized joint pain
dietary supplement (InstaflexTM Joint Support, Direct Digital, Charlotte, NC) compared to placebo on joint pain,
stiffness, and function in adults with self-reported joint pain. InstaflexTM is a joint pain supplement containing
glucosamine sulfate, methylsufonlylmethane (MSM), white willow bark extract (15% salicin), ginger root concentrate,
boswella serrata extract (65% boswellic acid), turmeric root extract, cayenne, and hyaluronic acid.
Methods: Subjects included 100 men and women, ages 50-75 years, with a history (>3 months) of joint pain, and
were randomized to Instaflex™ or placebo (3 colored gel capsules per day for 8 weeks, double-blind administration).
Subjects agreed to avoid the use of non-steroidal anti-inflammatory drugs (NSAID) and all other medications and
supplements targeted for joint pain. Primary outcome measures were obtained pre- and post-study and included joint
pain severity, stiffness, and function (Western Ontario and McMaster Universities [WOMAC]), and secondary outcome
measures included health-related quality of life (Short Form 36 or SF-36), systemic inflammation (serum C-reactive
protein and 9 plasma cytokines), and physical function (6-minute walk test). Joint pain symptom severity was assessed
bi-weekly using a 12-point Likert visual scale (12-VS).
Results: Joint pain severity was significantly reduced in Instaflex™ compared to placebo (8-week WOMAC, ↓37% versus
↓16%, respectively, interaction effect P = 0.025), with group differences using the 12-VS emerging by week 4 of the
study (interaction effect, P = 0.0125). Improvements in ability to perform daily activities and stiffness scores in Instaflex™
compared to placebo were most evident for the 74% of subjects reporting knee pain (8-week WOMAC function score,
↓39% versus ↓14%, respectively, interaction effect P = 0.027; stiffness score, ↓30% versus ↓12%, respectively, interaction
effect P = 0.081). Patterns of change in SF-36, systemic inflammation biomarkers, and the 6-minute walk test did not
differ significantly between groups during the 8-week study
Conclusions: Results from this randomized, double blind, placebo-controlled community trial support the use of the
Instaflex™ dietary supplement in alleviating joint pain severity in middle-aged and older adults, with mitigation of
difficulty performing daily activities most apparent in subjects with knee pain.
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Joint pain is reported by 32% of U.S. adults, and increases
with age reaching 50% prevalence among the elderly [1].
Joint pain is slightly more prevalent among women (33%)
than men (31%), and among white, non-Hispanic adults
(33%), than black, non-Hispanic adults (32%) and His-
panic adults (25%). The knee is the most common site of
joint pain regardless of age or gender. Joint pain is associ-
ated with substantial activity limitation, work disability,
and reduced quality of life. Adults with joint pain are more
likely to report arthritis-attributable activity limitations,
fair or poor health, inability to work, low sleep duration
(<6 hours per day), and psychological distress. Predictors
of knee pain include older age, weight gain and obesity,
and previous knee injury, with the combination of weight
loss with exercise a well-recognized intervention to allevi-
ate symptoms and improve function [2,3].
Conventional treatment of joint pain with non-steroidal
anti-inflammatory drugs (NSAIDs) and other analgesics is
associated with gastrointestinal and cardiovascular side ef-
fects, and other adverse health effects [4]. Use of alterna-
tive supplements is reported by 47% of individuals with
knee osteoarthritis, and well-designed human trials are
needed to identify effective analgesic alternatives [5]. The
most widely used and studied joint pain supplements
include those related to chondroprotection such as glu-
cosamine, chondroitin, methylsulfonylmethane, collagen
hydrolysates, and hyaluronic acid [6-8]. Herbal and neu-
traceutical products have been investigated including
avocado-soybean unsaponifiables, curcumin and turmeric
extract, epigallocatechin gallate and green tea extract, res-
veratrol, nobiletin and citrus fruits, omega-3 fatty acids,
cat’s claw, Boswella serrata, white willow bark, antioxi-
dants, ginger, cayenne, barberry, hu zhang, oregano, rose-
mary, Baikal skullcap, Chinese goldthread, Indian holy
basil, and many others [6,9-11].
Inflammation is a prominent mechanism leading to car-
tilage degeneration, and there is increasing realization that
therapy must involve both cartilage protection and anti-
inflammatory actions [7]. The Instaflex™ Joint Support sup-
plement (Instaflex) (Direct Digital, Charlotte, NC) features
a cocktail of eight chondroprotective and anti-inflammatory
ingredients that may relieve joint pain discomfort and
improve function. Ingredients include glucosamine sulfate
[12], methylsufonlylmethane [13-15], white willow bark ex-
tract [16], ginger root concentrate [17,18], Boswella serrata
extract [19,20], turmeric root extract [21], cayenne [22], and
hyaluronic acid [23]. Each of these ingredients has been
studied separately providing some scientific support for al-
leviation of joint pain, but the composite product has not
yet been tested in humans using a randomized, double-
blinded, placebo-controlled research design.
The primary purpose of this study was to assess the ef-
fect of 8-weeks ingestion of Instaflex compared to placeboon joint pain, stiffness, and function utilizing validated
questionnaires and the 6-minute walk test. Secondary out-
comes for this trial included the measurement of systemic
inflammation biomarkers.
Methods
Subjects
Subjects were recruited through mass advertising during a
one-month period, and included 108 men and women,
ages 50–75 years. Inclusion and exclusion criteria for this
study included:
1. Self-reported history (>3 months) of joint pain in
the knees, hip, ankles, shoulders, or hands.
Minimum symptom severity was ensured by using a
WOMAC pain index score of at least 2 points.
2. No history of regular NSAID use (e.g., ibuprofen,
aspirin) during the previous two weeks, and willingness
to avoid NSAIDs use during the 8-week study.
3. Not on other medications (e.g., analgesic gels,
arthritis medications, other anti-inflammatory drugs)
or supplements (in particular, glucosamine and
chondroitin) for joint pain for the previous two
weeks, and willing to avoid use of these during the
8-week study.
4. No serious medical problems (current cancer case,
severe rheumatoid arthritis, recent heart attack,
recent stroke, congestive heart failure, ulcers, kidney
disease, or other disease that would interfere with
study participation).
5. No psychiatric disorder or other condition that
might interfere with self-assessment ability.
6. Willingness to follow all study procedures including
randomization to one of two groups, and to stay
weight stable during the study.
7. Able to walk for at least 6 min at a moderate-to-
brisk pace.
8. No history of allergic reactions to shellfish products
or products containing aspirin.
Written informed consent was obtained from each sub-
ject, and the experimental procedures were approved by
the institutional review board for human studies at Appa-
lachian State University. Paracetamol (i.e., acetaminophen
as found in Tylenol) was allowed as a rescue medicine for
pain during the study as needed, with usage recorded.
Research design
This study employed a placebo-controlled, randomized,
double-blind design with two groups. Subjects were re-
cruited from one site in the Charlotte, NC, metropolitan
area, and randomized using a stratified block design to
ensure similar numbers of males and females to one of
two groups: Instaflex™ Joint Support (Instaflex) or placebo.
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during an 8-week period. Blood samples were drawn from
an antecubital vein with subjects in the seated position
pre- and post-study in the late afternoon. During the pre-
study lab visit, subjects reviewed and signed the consent
form, completed a medical-health questionnaire to verify
medical history and lifestyle habits, completed a 2-week
retrospective symptom log, and were measured for height
and weight. Height was measured using a stadiometer,
and body weight measured using a digital scale (Tanita
Corporation of America, Inc., Arlington Heights, IL). Sub-
jects completed the Western Ontario and McMaster
Universities (WOMAC) and health-related quality of life
questionnaires (Short Form 36 or SF-36). Subjects then
engaged in the 6-minute walk test on an indoor track. Fi-
nally, each subject received a supplement organizer tray
with 8-weeks supply and written instructions for taking
the supplements. These outcome measures were repeated
during the second lab visit.
Instaflex joint support supplement
Supplements (Instaflex, placebo) were prepared in colored
gel capsules (3 per day, identical looking), and given to the
subjects in supplement organizer trays. Subjects ingested 3
capsules/day: one capsule each in the morning, at noon-
time, and in the evening. The placebo capsules contained
magnesium stearate, an inert substance. Compliance was
monitored with bi-weekly email messages, and by counting
unused capsules when subjects returned the supplement
trays at the end of the 8-week study. If subjects missed
one, two, or three days of taking supplements, subjects
were asked to double up usage until back on schedule.
Subjects missing more than three days of taking the sup-
plements were asked to leave the study. The Instaflex
supplement contained the following ingredients (in 3
capsules): Glucosamine sulfate (1500 mg), methylsufonlyl-
methane (MSM) (500 mg), white willow bark extract (stan-
dardized to 15% salicin) (250 mg), ginger root concentrate
(50 mg), boswella serrata extract (standardized to 65%
boswellic acid) (125 mg), turmeric root extract (50 mg),
cayenne 40 m H.U. (50 mg), and hyaluronic acid (4.0 mg).
WOMAC questionnaire
The WOMAC™ Index is a tri-dimensional self-administered
questionnaire to assess joint pain (five items), stiffness
(two items), and physical function (16 items), and can be
completed in less than 5 minutes [24]. The Likert version
was used in this study, with five response levels for each
item, representing different degrees of intensity (none,
mild, moderate, severe, or extreme) that were scored from
0 to 4. Scores for the WOMAC were determined by add-
ing items scores within each index (pain, stiffness, and
function), and an aggregate score by adding scores from
the three indexes. The worst possible severity scores forpain, stiffness, function (limitation of physical function),
and total were 20, 8, 64, and 92 points, respectively.
SF-36 questionnaire
The SF-36 is a generic health-related quality of life instru-
ment [25]. The 36 items in the SF-36 cover eight domains
(physical functioning, limitations due to physical health,
bodily pain, general health, vitality, social functioning, and
limitations related to emotional and mental health) and
the physical and mental summary scales. The scores for
the SF-36 scales range from 0 to 100, with a higher score
indicating better health status.
2-week retrospective symptom logs and 12-point likert
visual scale (12-VS) for joint pain
The retrospective symptom logs were completed every
two weeks during the study, and included questions on di-
gestive health (constipation, heartburn, bloating, diarrhea,
and nausea), hunger levels (morning, afternoon, and even-
ing), energy levels (morning, afternoon, and evening), sick-
ness (fever, cough, sore throat, stuffy nose, runny nose,
and headache), pain (joint, muscle, and back), allergies,
stress level, focus/concentration, and overall well-being
[26]. For each of these including joint pain (12-VS), sub-
jects were asked to place an “X” in one of 12 boxes (la-
beled 1 to 12) lined up in one row that best matched the
symptoms or feelings experienced during the past two
weeks, with 1 = none at all, 3 = low, 6 =moderate, 9 = high,
and 12 = very high levels of the symptom or feeling.
6-minute walk test
The 6-minute walk test is commonly used to assess
whether or not an intervention is associated with im-
proved ability to walk faster during a 6-minute period in
individuals with various health problems [27]. Subjects
dressed in comfortable clothing and shoes, and were
instructed to walk as far as possible in 6 minutes on an
indoor track while receiving encouragement from the
staff. A practice 3-min walk test was conducted prior to
recording measurements during the 6-minute walk test.
Blood measures
Serum C-reactive protein (CRP) and a serum comprehen-
sive diagnostic chemistry panel were analyzed by the clin-
ical hematology laboratory at the Carolina Medical Center
(Charlotte, NC). CRP was measured using an LX-20 clin-
ical analyzer (Beckman Coulter Electronics, Brea, CA).
Total plasma concentrations of four inflammatory cyto-
kines (interleukin-6 [IL-6], tumor necrosis factor alpha
[TNFα], IL-8, and IL-10) were determined using an elec-
trochemiluminescence based solid-phase sandwich im-
munoassay (Meso Scale Discovery, Gaithersburg, MD).
All samples and provided standards were analyzed in du-
plicate, and the intra-assay coefficient of variation (CV)
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from 2.4% to 9.6%, for all cytokines.
Statistical procedures
Data analysis was performed for the 100 subjects success-
fully completing the study. Data are expressed as mean ±
SE. Subject characteristics were compared using independ-
ent Student’s t tests between the treatment (Instaflex) and
placebo groups (Table 1). The blood biomarker data was
analyzed by 2 (groups) × 2 (time points) repeated measures
ANOVA, where blood biomarker level (continuous vari-
able) was the response variable; group, time, and group ×
time interaction effect were predictor variables. Each bio-
marker was analyzed separately. The composite scores
from questionnaires were also analyzed by 2 × 2 repeated
measures ANOVA. Individual answers in questionnaires
and symptom log were analyzed by generalized estimating
equations, where each individual question (categorical
variable) was the response variable; group, time, and
group × time (2 × 2 for questionnaires, and 2 × 5 for symp-
tom log) interaction effect were predictor variables. Each
individual question was analyzed separately. For both re-
peated measures ANOVA and generalized estimating
equation, response variables with significant group × time
interaction effect were considered to be significantly af-
fected by the Instaflex supplement, and the interaction
P-value was used for the group contrast. For symptom log
variables with five time points, P-values at each time point
represent independent student’s t-test contrasts between
groups for changes from pre-study. All analyses were per-
formed in SAS (version 9.2, SAS Institute, Inc., Cary, NC).
Results
Of the 108 subjects recruited into the study, 101 (N = 50
Instaflex and N = 51 placebo) completed all aspects of the
study. Subjects dropping out of the study (N = 4 from
Instaflex, N = 3 from placebo) cited health issues (N = 4)
or noncompliance with the supplementation regimen (N =
3). One subject (Instaflex) was removed the data analysis
because rescue medication use reached daily levels by the
end of the study. All other subjects complied fully withTable 1 Subject characteristics and pre- and post-study (8 we
Variable Instaflex (N = 49; 41 F, 8 M) Placebo (N =
Age (yrs) 57.6 ± 0.9 58.3 ± 0.8
Height (m) 1.67 ± 0.01 1.65 ± 0.01
Body mass (kg)
Pre-Study 89.3 ± 2.6 84.8 ± 2.3
Post-Study 89.4 ± 2.6 84.7 ± 2.3
BMI
Pre-Study 31.6 ± 0.9 30.9 ± 0.8
Post-Study 31.6 ± 0.9 30.8 ± 0.8study requirements and the supplementation protocol, and
no unused capsules were left in the supplement trays. Sub-
ject characteristics and pre- and post-study body mass and
BMI values are compared between groups in Table 1, with
no significant group differences measured. Of the 100 sub-
jects completing the study, 55% of the subjects had a
BMI ≥ 30 kg/m2 (obese), and 30% a BMI of 25–29.9 kg/m2
(overweight). Subjects were predominately female, with
eight males in the Instaflex group and 9 males in the pla-
cebo group (gender Chi-square P-value = 0.861). For all
subjects combined, 74.2% reported knee pain, 55.7% upper
limb joint pain, 41.2% hip pain, 24.7% lower limb joint
pain, and 18.6% back pain. Thirty-one percent of subjects
reported arthritis, but this was not confirmed through
physician diagnosis. Chi-square analysis revealed no group
differences for these percentages.
The pattern of change in the total WOMAC score
tended to be different between groups (Instaflex 29.4 ±
2.0 to 19.0 ± 1.9, placebo 30.0 ± 2.0 to 24.6 ± 1.0, inter-
action effect P = 0.074). Joint pain severity was signifi-
cantly reduced in Instaflex compared to placebo (8-week
WOMAC, ↓37% versus ↓16%, respectively, interaction
effect P = 0.025) (Figure 1). Interaction effects for the
WOMAC joint stiffness (↓26% versus ↓18%, respectively,
interaction effect P = 0.325) and joint function index
scores (↓36% versus ↓19%, respectively, interaction effect
P = 0.117) were not significant.
In a separate analysis of the 74% of subjects reporting
knee pain (73% in Instaflex, 75% in placebo), decreases
in WOMAC total and pain, stiffness, and function index
scores were greater for Instaflex compared to placebo
[8-week WOMAC total score, ↓38% versus ↓17%, re-
spectively, interaction effect P = 0.018 (Figure 2); pain
score, ↓39% versus ↓11%, respectively, interaction effect
P = 0.014; stiffness score, ↓30% versus ↓12%, respectively,
P = 0.081; function score, ↓39% versus ↓14%, respect-
ively, P = 0.027] (Figure 3).
Joint pain symptom severity assessed bi-weekly using
the 12-point Likert visual scale (12-VS) from the symptom
logs showed significant reductions for Instaflex compared
to placebo starting at week 4 (interaction effect, P = 0.0125)eks) body mass and BMI (N = 100) (mean ± SE)
51; 42 F, 9 M) Range P-Value (t-test or ANOVA)
50-75 0.554
1.46-1.84 0.106
54.5-140.9 0.422
21.1-48.0 0.536
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Figure 1 WOMAC joint pain in Instaflex compared to placebo (interaction effect, P = 0.025). The P-value in the graph represents the
pre-to-post study contrast between Instaflex and placebo groups.
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spective symptom logs showed no group differences (data
not shown).
Patterns of change in responses from the SF-36 (data not
shown, total score, interaction effect, P = 0.986), systemic
inflammation biomarkers (Table 2), and the 6-minute walk
test (Instaflex 561 ± 10.8 to 558 ± 10.7 meters, placebo 558 ±
10.0 to 545 ± 10.7 meters, interaction effect P = 0.233) did
not differ significantly between groups during the 8-week
study. Diagnostic chemistry panels revealed no group
differences over the 8-week study for all liver and kid-
ney function, and metabolic measures including albumin,
alkaline phosphatase, alanine aminotransferase, aspartate
aminotransferase, blood urea nitrogen, calcium, chloride,
carbon dioxide, creatinine, glucose test, potassium, so-
dium, total bilirubin, and total protein (data not shown).
Discussion
This 8-week randomized, double-blind, placebo-controlled
study with 100 community adults reporting joint pain0
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Figure 2 WOMAC total scores in subjects reporting knee pain (interac
pre-to-post study contrast between Instaflex and placebo groups.showed that Instaflex is efficacious and safe to use, with no
adverse symptomology or negative effects on general me-
tabolism and liver and kidney function. Instaflex caused
significant reductions in joint pain for the whole group.
Among the 74% of subjects with knee pain, difficulties per-
forming daily activities were attenuated. Joint pain reduc-
tion effects from Instaflex become apparent by the fourth
week of supplementation, and occurred without changes in
systemic inflammation or distance walked in six minutes.
The primary outcomes of this study were the pain, stiff-
ness, and function indexes of the WOMAC. The mag-
nitude of decrease in joint pain for all subjects in the
Instaflex (↓37%) compared to placebo (↓16%) group, and
decrease in difficulties performing daily activities for those
with knee pain (↓39% vs. ↓14%), is comparable to or higher
than what has been reported in other studies using chon-
droprotective or anti-inflammatory dietary supplements in
subjects with osteoarthritis [8,12-14,28-33]. For compari-
son with a lifestyle change factor, one study of 250 subjects
showed that weight loss of 5% and higher (median 11.1 kg)Placebo (N=36)
t-Study (8 weeks)
tion effect, P = 0.018). The P-value in the graph represents the
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Figure 3 WOMAC function scores in subjects reporting knee pain (interaction effect, P = 0.027). The P-value in the graph represents the
pre-to-post study contrast between Instaflex and placebo groups.
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after adjustment for age, sex, and baseline weight [3].
Most previous studies testing the efficacy of dietary sup-
plements on joint pain reduction have compared placebo
to one or two of the chondroprotective components in-
cluding glucosamine (typical dose, 1,000-1,500 mg/day),
chondroitin sulfate (800–1,200 mg/day), methylsulfonyl-
methane (1,500 mg/day), collagen hydrolysates, and hyalur-
onic acid [6-8]. Results from these studies have been mixed
[6,8,12,13,15,23,28] and the most recent meta-analysis of
glucosamine and chondroitin was non-supportive [29].
There is increasing evidence that nutraceutical-based com-
binations of chondroprotective and/or anti-inflammatory
components are modestly effective in reducing joint pain
within 4–16 weeks without measurable side effects [9,11].3
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Figure 4 Joint pain symptom severity assessed bi-weekly using the 1
P = 0.0125). P-values at each time point represent independent student’s tInstaflex (3 capsules daily portion) combines 1500 mg of
glucosamine sulfate, 500 mg methylsufonlylmethane, and
4 mg hyaluronic acid with several anti-inflammatory sub-
stances including white willow bark extract, ginger root
concentrate, boswella serrata extract, turmeric root ex-
tract, and cayenne. Other combinations of nutraceuticals,
botanicals, and dietary supplements that have shown effi-
cacy in reducing joint pain symptoms in double-blind,
placebo-controlled studies include Phellodendron amurense
bark and Citrus sinensis peel extracts standardized to ber-
berine and polymethoxylated flavones [30], lemon verbena
extract (14% verbascoside) with fish oil [31], a product
containing dried extracts from six Asian herbs [32], and
a mixture of glucosamine, chondroitin, and quercetin
glycoside [33].weeks 6-weeks 8-weeks
Placebo
=0.039 P=0.019
P=0.080
2-point Likert visual scale (12-VS) (2 × 5 interaction effect,
-test contrasts between groups for changes from pre-study.
Table 2 Serum C-reactive protein (CRP) and selected plasma cytokine data pre- and post-study (8 weeks) (mean ± SE)
Variable Instaflex (N = 49) Placebo (N = 51) Interaction effect, P-Value
CRP (mg/L)
Pre-Study 4.05 ± 0.64 3.77 ± 0.43 0.518
Post-Study 3.56 ± 0.56 3.50 ± 0.41
IL-6 (pg/ml)
Pre-Study 2.12 ± 0.20 1.80 ± 0.20 0.991
Post-Study 2.16 ± 0.17 1.84 ± 0.17
IL-8 (pg/ml)
Pre-Study 5.39 ± 0.35 5.55 ± 0.34 0.143
Post-Study 6.41 ± 0.40 7.13 ± 0.39
TNF-α (pg/ml)
Pre-Study 4.19 ± 0.16 4.32 ± 0.16 0.380
Post-Study 4.10 ± 0.17 4.32 ± 0.17
IL-10 (pg/ml)
Pre-Study 1.24 ± 0.11 1.39 ± 0.10 0.760
Post-Study 1.23 ± 0.08 1.35 ± 0.08
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has been studied separately for influences on joint pain
management, but little is known regarding potential
synergistic effects when these are combined in smaller
amounts than used in single component studies. The
active principle in white willow bark extract is salicin, an
alcoholic β-glucoside closely related to acetylsalicylic
acid in aspirin. The daily dose of Instaflex supplement
contains approximately the equivalent of ¼ an aspirin
tablet. Studies using larger doses of white willow bark
providing about 240 mg/day salicin for periods of up to
six weeks generally support modest pain relief [16,34].
More than 100 compounds have been reported from
ginger, including gingerols that possess anti-inflammatory,
analgesic, and cardiotonic effects [18,35]. Ginger has gained
considerable attention in developed countries in recent
years, especially for its use in the treatment of inflammatory
conditions, and a study of patients with osteoarthritis
showed a moderate effect of ginger extract in reducing
symptomatology [17]. Boswellia serrata is Indian frankin-
cense or Salai, and has been used for centuries as a treat-
ment for arthritis. Animal studies and pilot clinical trials
support the potential of Boswellia serrate gum resin extract
in the treatment of a variety of inflammatory diseases in-
cluding osteoarthritis [19,20,36], and a study of 75 patients
with osteoarthritis showed that Boswella serrate extract
safely reduced pain and improved physical functioning [20].
Turmeric contains over 300 different components includ-
ing the active ingredient curcumin (3–5%) [37]. In vitro
and animal research shows curcumin is a highly pleiotropic
molecule capable of interacting with numerous molecular
targets involved in inflammation [21]. Few human trials
have been published, but one study of 107 patients withknee osteoarthritis showed that turmeric extract was as effi-
cacious as ibuprofen in alleviating symptoms [38]. Cayenne
or red pepper spice contains capsaicin that activates the
transient potential receptor vanilloid 1 (TRPV1) channel in-
volved in some aspects of inflammation control [39]. One
review of several studies indicates that cayenne compared
to placebo exerts modest effects for pain relief [22].Conclusions
This 8-week randomized community trial with middle-
aged and older adults supports the use of Instaflex in redu-
cing joint pain and improving the ability to perform daily
activities, especially in subjects reporting knee pain. Joint
pain reduction in the Instaflex compared to placebo group
was measurable by the fourth week of the study, indicating
a relatively rapid response. Symptom logs and diagnostic
chemistries did not reveal any adverse effects associating
with the oral ingestion of Instaflex during the 8-week
period of this study. Instaflex contains eight chondropro-
tective and anti-inflammatory ingredients in amounts that
are below levels commonly used in other studies evaluating
efficacy of single components. Further research should help
reveal whether this cocktail of nutraceuticals can be opti-
mized further by changes in relative quantities and ingredi-
ents, and underlying mechanisms responsible for the joint
pain reduction measured in this study.Abbreviations
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